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Teaser: Due to the clinical significance of drug interactions with herbs, there is a 
strong necessity to identify drugs that may interact with herbal medicines in drug 
development.  
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Abstract 
To date, a number of clinically important drugs have been identified that interact with 
commonly-used herbs. These drugs include (amongst others) warfarin, midazolam, 
digoxin, amitriptyline, indinavir, cyclosporine, tacrolimus and irinotecan. 
Importantly, many of these drugs have very narrow therapeutic indices. Most of them 
are substrates for cytochrome P450s (CYPs) and/or P-glycoprotein (P-gp). Because 
drug-herb interactions can significantly affect circulating levels of drug and, hence, 
alter the clinical outcome, the identification of drugs that interact with commonly-
used herbal medicines has important implications in drug development. In silico, in 
vitro, animal and human studies are often used to identify drug interactions with 
herbs. We propose that drug-herb and herb-CYP interaction studies should be 
incorporated into drug development. 
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1 Introduction 
Herbal medicines are becoming popular worldwide, despite their mechanisms of 
action being generally unknown, the lack of evidence of efficacy, and inadequate 
toxicological data. An estimated one third of adults in developed nations and more 
than 80% of the population in many developing countries use herbal medicines in the 
hope of promoting health and to manage common maladies such as colds, 
inflammation, heart disease, diabetes and central nervous system diseases. To date, 
there are more than 11,000 species of herbal plants that are in use medicinally and, of 
these, about 500 species are commonly used in Asian and other countries. These herbs 
are often co-administered with therapeutic drugs, raising the potential of drug-herb 
interactions, which may have important clinical significance based on an increasing 
number of clinical reports of such interactions.   
 
The interaction of drugs with herbal medicines is a significant safety concern, 
especially for drugs with narrow therapeutic indices (e.g. warfarin and digoxin). 
Because the pharmacokinetics and/or pharmacodynamics of the drug may be altered 
by combination with herbal remedies, potentially severe and perhaps even life-
threatening adverse reactions may occur. Due to the clinical significance of drug 
interactions with herbs, it is important to identify drugs and compounds in 
development that may interact with herbal medicines. Timely identification of such 
drugs using proper in vitro and in vivo approaches may have important implications 
for drug development. 
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2 Drugs that interact with herbal medicines in humans 
Literature searches were performed using the following databases: Medline (via 
Pubmed), Biological Abstracts, Cochrane Library, and Embase (all from their 
inception to March 2007). All human in vivo studies relating to drug-herb interactions 
were included, whereas data from animal and in vitro drug interaction studies were 
generally excluded, except for those exploring mechanisms for drug-herb interactions. 
Only literatures in English were included. Human studies included case reports, case 
series, clinical trials or other types of studies. 
 
A total of 34 drugs were identified that interacted with herbal medicines in humans (
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Table 1). These drugs mainly include anticoagulants (warfarin, aspirin and 
phenprocoumon), sedatives and antidepressants (midazolam, alprazolam, 
amitriptyline and trazodone), anti-HIV agents (indinavir and saquinavir), 
cardiovascular drugs (digoxin, nifedipine and propranolol), immunosuppressants 
(cyclosporine and tacrolimus) and anticancer drugs (irinotecan and imatinib). 
However, several other drugs, including ibuprofen, cilostazol, clopidogrel, 
acetaminophen, carbamazepine, mycophenolic acid, ritonavir and pravastatin are 
reported not to interact with herbal medicines [1-3]. 
 
Of the drugs identified as interacting with herbal medicines, most were administered  
orally in long term regimens. There are a number of drug-drug interactions in humans 
that were associated with combinations of these drugs. For example, cyclosporine has 
been reported to alter the pharmacokinetics and/or pharmacodynamics of a series of 
drugs, including repaglinide [4], statins [5], and levofloxacin [6]. Additionally, a 
number of drugs such as ezetimibe [7] and carvedilol [8] can alter the 
pharmacokinetics and/or pharmacodynamics of cyclosporine.   
 
Many of the drugs in 
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Table 1, including warfarin, digoxin, theophylline, and cyclosporine, have narrow 
therapeutic indices (warfarin: 2.0-3.0 of target international normalized ratio for most 
indications; digoxin: 0.5-2.0 ng/ml; theophylline: 10-20 µg/ml; and cyclosporine: 
150-400 ng/ml) [9].  Thus, a small change in their plasma concentration could lead to 
a marked alteration in their therapeutic effect and/or toxicity. Warfarin is one of the 
most frequently used oral anticoagulants for prevention of blood clotting. There are 
some reports of interactions between warfarin and herbs such as St John's wort, 
danshen, Dong quai, ginseng and ginkgo in patients on constant warfarin therapy 
[1,10]. Pharmacokinetic modulation of warfarin is common, but severe toxicity, such 
as postoperative bleeding, have been reported [1,10]. Combination of digoxin with St 
John’s wort, or Siberian ginseng significantly affects its plasma concentration [1,10]. 
 
Of the 34 drugs that were found to interact with herbs, 28 (82.4%) are substrates for 
various cytochrome P450s (CYPs), in particular, CYP3A4 and CYP2C9. Warfarin is 
extensively metabolized by CYP3A4 and CYP2C9, thus the anticoagulant effect of 
warfarin is likely to be affected when its metabolism (in particular that of its S-
enantiomer) is compromised by combination with herbal remedies that are capable of 
modulating these enzymes [11]. In addition to warfarin, alprazolam, imatinib, 
midazolam and amitriptyline are also substrates for CYP3A4. CYP3A4 is the most 
abundance isozyme in the human liver, representing approximately 40% of total 
hepatic CYP contents and is responsible for the metabolism of more than 50% of all 
prescribed drugs [12,13]. All CYPs are subject to inhibition or induction by a variety 
of xenobiotics, including drugs and herbal medicines. Importantly, the expression of 
CYP3A4, CYP3A5, CYP2B6 and CYP2C8 is tightly regulated by the nuclear factor 
pregnane X receptor (PXR/NR1I2) which is activated by a variety of structurally-
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distinct ligands including certain herbal components such as hyperforin from St 
John’s wort [12,14-16]. A number of drug-drug interactions have been found to be 
mediated by CYP modulation, resulting in altered drug clearance and effect [17].  
 
Ten of the 34 drugs (29.4%) that interact with herbs have been identified as substrates 
for P-glycoprotein (P-gp), a well-known drug transporter. These include cyclosporine, 
digoxin, fexofenadine, imatinib, indinavir, irinotecan, simvastatin, saquinavir and 
tacrolimus. Interestingly, these 10 drugs, except digoxin and fexofenadine, are also 
substrates for CYP3A4. Thus, 8 of the 34 drugs are dual substrates (23.5%) for both 
CYP3A4 and P-gp. P-gp in the intestine, liver and kidney plays important roles in the 
absorption, distribution, or excretion of drugs. In common with CYP3A4, P-gp can be 
induced and inhibited by a number of xenobiotics, including drugs and herbal 
medicines [18] and it is also regulated by PXR. [19,20]  Theoretically, a drug which is 
a dual substrate for CYP3A4 and P-gp has a much higher potential for interaction 
with herbs that also modulate CYP3A4 and P-gp. For example, carbamazepine is 
metabolized by multiple CYPs [21], but it is not a substrate of P-gp [22]. This reduces 
its potential for herbal interaction and as shown in Table 1, it appears not to interact 
with herbal medicines.  
 
3 Mechanisms for drug interactions with herbal medicines 
The underlying mechanisms for most reported drug interactions with herbal 
medicines have not been fully elucidated. As with drug-drug interactions, both 
pharmacokinetic and pharmacodynamic mechanisms are implicated in these 
interactions (Figure 1). Alterations in absorption, metabolism, distribution or 
excretion of drugs are the cause for pharmacokinetic interactions. Altered drug 
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metabolism by herbal medicines is often a result of CYP induction and/or inhibition 
[17]. The most well-studied and understood example of this is the induction of 
CYP3A4 and CYP2B6 by St John's wort in humans [23-26].  Of the components of 
St. John’s wort, hyperforin is purported to be the active constituent and it is the most 
potent agonist for PXR with a Ki of 27 nM [23]. Due to the important role of P-gp in 
drug transport and excretion, modulation of P-gp by herbal medicines may have 
significant pharmacokinetic consequences [18]. St John’s wort induces intestinal PgP 
in vitro and in vivo [27-29]. Oral administration of St John’s wort for 14 days in 
healthy volunteers resulted in a 1.4-fold increase in P-gp expression [27]. The 
substrates of P-gp, fexofenadine and digoxin which are often used as probes for 
examining P-gp activity in vivo, were found to have increased clearance in healthy 
subjects treated with St John’s wort [30]. However, there is rare clinical evidence for 
altered protein binding of drugs by herbal medicines. Given that many herbal 
components are highly bound by plasma proteins, they may displace the drugs from 
the binding sites  [1]. 
 
Herbal medicines are often administered orally and they can attain moderate to high 
concentrations in the gut lumen (the primary site of absorption for most orally-
administered drugs) and liver, and may exert a significant effect on enterocytes and 
hepatocytes. Both P-gp and CYP3A4 are abundantly expressed in the villus tip of 
enterocytes and hepatocytes [31]. The interplay of both intestinal P-gp and CYP3A4 
has a strong effect on the bioavailability of most orally-administered drugs including 
cyclosporine, midazolam, talinolol, statins, HIV protease inhibitors and verapamil 
[31]. Thus, the modulation of intestinal and hepatic P-gp and CYP3A4 by herbal 
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medicines represents a potentially important mechanism by which the bioavailability 
of coadministered drugs can be modulated. 
 
Altered pharmacokinetics almost inevitably leads to a significant change in response 
to drugs that have a narrow therapeutic indices; however, given that a single herbal 
preparation may contain more than 100 components, all of which may have unknown 
biological activities, a herb can potentially mimic, increase, or reduce the effects of 
co-administered drugs through simultaneous effects on the same drug targets (Figure 
1) [10].  If the effect of the drug in combination with the herbal medicine is enhanced 
(e.g. synergistic or additive effect), unfavourable on target toxicity may occur. In 
contrast, some herbal remedies may contain compounds with antagonistic properties, 
which are likely to reduce drug efficacy and produce therapeutic failure. The 
synergistic or antagonistic effects between herbs and drugs often result from the 
competitive or complementary effect of the drug and the coadministered herbal 
constituents at the same drug targets [10].  
 
4 Clinical significance of identification of drugs that may interact with herbs 
When a drug’s clearance is significantly altered, or its drug targets are the same as the 
herbal components, a clinically important drug interaction with herbs may occur 
(Figure 2). Herbal medicines that are able to modulate intestinal and hepatic CYPs 
and P-gp often alter the bioavailability and clearance of coadministered drugs [1].  
Many commonly-used herbal medicines have been shown to alter the plasma 
clearance of therapeutic drugs. For example, long-term treatment of St John's wort 
reduces the plasma levels of co-administered cyclosporin, amitriptyline, digoxin, 
indinavir, nevirapine, oral contraceptives, warfarin, phenprocoumon, theophylline or 
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simvastatin [32]. Garlic preparations decrease the plasma concentrations of 
saquinavir, but not ritonavir [1,10,33].  Consequently, drug efficacy and toxicity may 
be changed. Decreased blood trough concentrations of cyclosporine have been 
observed in patients also taking St John’s wort and this was associated with transplant 
graft rejection observed in all of these cases [1,10].  
 
There are few clinical studies addressing the effect of combined herbal medicines on 
drug efficacy due to pharmacodynamic mechanisms. Patient cases have been reported 
where the combined use of St John’s wort and selective serotonin re-uptake inhibitors 
(e.g. sertraline and nefazodone) caused symptoms characteristic of central 
serotonergic syndrome in the elderly [34-38]. This syndrome is characterized by a 
combination of any of the following symptoms: confusion, agitation, tremor, 
diaphoresis, hyperreflexia, nausea, diarrhoea, lack of co-ordination, coma, flushing or 
rhabdomyolysis [39].  This is mainly caused by inhibitory effect of St John’s wort on 
serotonin transporters in the central nervous system [39]. 
 
This may lead to adverse reactions that are sometimes life-threatening or lethal [40]. 
For example, when St John's wort was combined with oral contraceptives 
(ethinylestradiol/desogestrel), loperamide, or selective serotonin-reuptake inhibitors 
(e.g. sertraline, paroxetine, and nefazodone), it caused intermenstrual bleeding, 
delirium, or mild serotonin syndrome in some patients [41-43]. Ginseng induced 
mania when used concomitantly with phenelzine [44]. Ginkgo raised blood pressure 
when combined with a thiazide diuretic and coma when combined with trazodone 
[45,46].   Garlic may also enhance the effect of hypoglycaemic drugs. A woman 
taking a curry containing garlic and karela (Momordica charantia) while on 
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chlorpropamide therapy experienced enhanced hypoglycemic response. [47] Kava 
caused a semicomatose state when given concomitantly with alprazolam [48]. 
 
The clinical importance of drug interactions with herbs depends on factors that are 
related to coadministered drugs (dose, dosing regimen, administration route, 
pharmacokinetic and therapeutic range), herbs (species, dose, dosing regimen, and 
administration route) and patients (genetic polymorphism, age, gender and 
pathological conditions) [49]. Generally, a doubling or more in drug plasma 
concentration has the potential for enhanced drug effects and/or appearance of 
adverse effects [1]. However, less marked changes may still be clinically important 
for drugs with a steep concentration-response relationship or a narrow therapeutic 
index. In most cases, the extent of drug interactions with herbs varies markedly 
among individuals, depending on inter-individual differences in drug metabolizing 
enzymes and transporters, co-medication with other drugs, age and many of other 
factors [18,50]. 
 
5 Approaches to identifying drugs that may interact with herbal medicines 
To avoid or minimize toxic drug-herb interactions, it is important to identify drugs 
that can interact with herbs using proper in vitro and in vivo models in the early stages 
of drug development (Figure 3). Such models have very different cost, reliability and 
possibility for high throughput studies. Thus, these models may be used in 
combination to obtain enough information that is useful for providing warning and 
proper advice to patients in clinical practice.   
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There is an increasing use of in silico methods to study CYPs, Phase II enzymes, P-gp 
and their interactions with xenobiotics, including herbs [51,52]. The in silico methods 
mainly include simple rule-based modelling, structure-activity relationships, three-
dimensional quantitative structure-activity relationships (QSAR) and pharmacophore 
modelling [51]. Knowledge of substrate specificity and regulation of the CYPs is 
important, as this will provide information on the possible drug interactions with 
herbal medicines. A structure-activity relationship analysis has indicated that a 
furano-O-naphthoquinone in tanshinone analogues isolated from the roots of Salvia 
Miltiorrhiza is essential for cytotoxicity towards cancer cells [53]. A number of in 
vitro systems are available to investigate the potential for drug interactions with 
herbal medicines. For metabolic interactions, the major models include subcellular 
fractions (liver microsomes, cytosols and homogenates), precision-cut liver slices, 
isolated and cultured hepatocytes or liver cell lines, and cDNA-expressed enzymes 
[54,55]. For transport studies, Caco-2, MDCKII cells, oocytes with highly expressed 
drug transporters, membrane vesicles and cDNA-expressed drug transporters are 
widely used. Each of these systems has advantages and limitations, and a combination 
of these methods will provide the most accurate information on how herbal medicines 
affect CYPs and P-gp. For example, cultured human hepatocytes provide cellular 
integrity with respect to enzyme architecture, and allow the study of Phase I and II 
reactions and transport [23-25]; however, some transporters and enzymes are rapidly 
down-regulated after isolation of hepatocytes [56]. 
 
A guidance entitled “Drug Metabolism/Drug Interaction Studies in the Drug 
Development Process: Studies In Vitro” was published by the Food and Drug 
Administration (FDA) of the United States (see: http://www.fda.gov). We would 
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propose that in common with the in vitro drug-drug and drug-CYP interaction studies 
that have been incorporated into drug development, studies on drug-herb, herb-CYP 
and herb-P-gP interactions should also be included in the future. The application of 
high throughput approaches to the study of drug-herb, herb-CYP and herb-P-gP 
interactions is becoming possible  [57]. They are capable of handling the great 
number of herbal constituents (e.g. a single herb usually contains dozens of 
biologically active constituents), and have the ability to provide in vitro inhibition 
data as a criterion for monitoring drug-herb interactions involving CYPs or P-gp.  
 
Animal models are widely used for the evaluation of drug-herb interactions. When 
drug interactions with a herb are suspected to be likely or significant in animal 
studies, they should be confirmed by well-designed clinical studies. Selective and 
specific probes should be chosen for in vivo CYP and P-gp studies.  In some cases, 
pharmacogenetic studies can be incorporated to explore the interplay of genetic 
mutations and combined use of herbal medicines. 
 
6 Predicting a drug’s potential for interaction with herbal medicines 
It should be possible to predict drug-drug interactions assuming proper principles are 
followed. However, unlike the prediction of metabolic drug-drug interactions where 
there have been a number of successes with those drugs mainly metabolized by CYPs 
[58], the prediction of drug interactions with herbs appears to be more problematic. 
Prediction is hampered by the following factors associated with the drug, herb and/or 
patients: a) herb medicines often contain more than 100 constituents, with unknown 
amounts and inhibition/induction potency for CYPs and P-gp; b) the 
inhibitor/induction of CYPs and P-gp by herbal medicines may by temporally 
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distinguishable, depending on the herb’s dosing, administration route and tissues and 
many other factors; c) many herbal medicines are used chronically; d) considerable 
variability in the active contents of herbal constituents due to quality control 
problems; e) drug-related factors such as  presence of extra-hepatic metabolism; and 
active transport in liver; and f) patient-related factors including age, disease, renal and 
hepatic functions and genetic polymorphisms of CYP3A4 and other relevant CYPs and 
MDR1 that encodes P-gp. All these factors will contribute to the final outcome of 
drug interaction with herbal medicines.   
 
A simple qualitative prediction of the potential for drug interactions with herbal 
medicines can be made based on the pharmacological properties of the drugs. If a 
drug is a substrate for CYP3A4 and P-gp, its potential for interaction with herbal 
medicines would be high, in particular when the combined herbal medicines contain 
potent inhibitory and/or inducing components for CYPs and P-gp. Generally, it can be 
anticipated that a herbal medicine such as St John’s wort containing potent CYP3A4 
and P-gp inducers would increase the clearance and decrease the bioavailability of 
coadministered drugs that are primarily metabolized by CYP3A4 and transported by 
P-gp. 
 
Though it is difficult to predict precisely the potential of a drug to interact with herbal 
medicines, useful information may be obtained from in vitro models such as hepatic 
microsomes and hepatocytes. [59,60]  Generally speaking, prediction is possible when 
the following criteria are met: a) the clearance of the drug is predominantly through 
hepatic metabolism (>80%); b) the drug is not subjected to substantial Phase II 
reactions (e.g. conjugation) or other non-CYP metabolism; c) the liver is the primary 
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organ of metabolic clearance and d) the drug does not possess physiochemical 
properties that are associated with absorption problems (i.e. limited water solubility 
and low intestinal permeability).   
 
The effects of inhibition/induction of drug metabolism on in vivo pharmacokinetics 
are highly variable and depend on a number of factors associated with the drug and 
combined herbal medicine and patients. The following factors determine the degree of 
change in plasma concentration at steady-state caused by the drug-herb interaction in 
vivo [60,61]: 
• Route of administration (intravenous or oral, i.e., whether the drug and 
herb medicine undergo significant first-pass metabolism). 
• Fraction of hepatic clearance in total clearance. 
• Fraction of the metabolic process subjected to inhibition/induction in total 
hepatic clearance.  
• Unbound intrahepatic concentrations of the inhibitory or inducing 
components existing in combined herbal medicines.  
• Unbound concentrations of the drug (i.e. that concentration of drug 
available for the hepatocytes).  
• The metabolic kinetics of the drug by hepatocytes (e.g. Km and Vmax). 
• The extent of active transport of the drug by P-gp and other transporters. 
•  
7 Implications of identification of drugs that may interact with herbs in drug 
development 
Interactions of drugs with herbal supplements are difficult to anticipate because of the 
general lack of information characterizing their pharmacologic actions and 
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composition. The dramatic rise in the use of herbal medicine worldwide means that 
many more patients on conventional medicines are being exposed to herbal 
medicines. Thus, timely identification of drugs capable of interacting with herbs is 
important to remind drug scientists of the possible safety concerns arising from 
combined use of herbs with any prescribed medicines [62]. Existing knowledge 
advises us that many herbal preparations must not be taken at the same time with 
many other drugs that are substrates for CYP3A4 and P-gp.  
 
In many cases, patients think that herbal remedies are natural products and, thus, are 
safe. They are not willing, or do not think it is necessary, to mention the types and 
doses of herbal remedies being used to clinicians, so there is little knowledge of who 
is taking these products and for what indications [63]. As such, drug interactions with 
herbal medicine are highly likely to be significantly under-reported and 
underestimated, and are probably more frequently than drug-drug interactions. 
 
Because CYP3A4 is involved in the oxidative metabolism of over 50% of current 
therapeutic drugs, herb remedies, such as St John’s wort, that induce this enzyme is 
highly likely to interact with many more drugs than previously reported [62]. To date, 
only a very small proportion of currently available drugs have been investigated for 
their potential interaction with herbs, such as St John’s wort and ginkgo, in humans. 
Thus, further well-designed clinical studies are certainly required to gain knowledge 
of drug interactions with herbs. The critical examination of interactions between herbs 
and drugs requires the ability to accurately determine not only the presence of altered 
metabolism and transport but also the ability to quantitate the extent of the interaction 
and clinical consequences in drug development.  
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The majority of clinical trials looking at efficacy excluded patients already taking 
prescribed drugs and therefore did not investigate the potential interactions with 
combined herbal remedies. Some clinical trials, however, did include patients taking 
medication for hypertension, circulatory disorders, bronchial asthma and menopausal 
symptoms with no evidence of any interactions between them and herbs [1]. The 
majority of interactions identified to date involve medicines that often require regular 
monitoring of blood levels. However, the interaction identified with oral 
contraceptives, without blood monitoring, is likely to effect a large population of 
individuals. Given that the number of medicines that currently require monitoring is 
low, compared with the number of medicines on the market that are metabolized by 
either CYP1A2, 2C9 and 3A4, it can be anticipated that more drug interactions with 
herbs will be identified and reported in the future.  
 
Since drug-herb combinations are often encountered in clinical practice and drug-herb 
interactions have important clinical and toxicological implications, a proper design of 
drugs that have minimal potential for herbal interaction has important implications in 
drug development [62]. It appears that the chemical properties of a drug critical for 
herbal interaction include (i) being a CYP substrate, (ii) being a P-gp substrate, and 
(iii) preponderance of CYP inducers and/or inhibitors. Thus, any newly developed 
drugs which are identified to be CYP and/or P-gp substrates have a potential for 
interactions with commonly used herbs. 
 
A possible approach to overcoming unfavourable drug interactions with herbal 
remedies is to design new drugs that are so-called “hard drugs” which are not 
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metabolized by CYPs and/or not transported by P-gp [62]. The concept of “hard 
drugs” was first proposed by Ariens [64]. These drugs are non-metabolizable, 
excreted through either the bile or kidney with simple kinetics. Thus, their 
pharmacokinetics is simplified and, usually, is predictable. When these drugs are 
administered, the potential for interactions with combined herbal remedies will be 
greatly reduced. 
 
For new drug application, its potential for CYP interactions is needed by FDA and 
subsequently in vitro drug-drug and drug-CYP interaction studies have been 
incorporated into drug development. Given that drug-herb interactions in humans are 
increasingly reported and fatal events are possible, studies on drug-herb, herb-CYP 
and herb-P-gp interactions should also be included and implemented at the early stage 
of drug development. With the current techniques, it is increasingly possible to 
identify drugs that are highly likely to interact with herbs. By screening drug 
candidates for possible interactions with CYPs and P-gp, it is possible to identify and 
eliminate such chemicals at early stages of development. 
 
If the drugs have to be used in combination with herbal remedies, in some instances 
rational use of such drugs becomes necessary, including the use of a safe drug 
combination regimen, dose adjustment, and discontinuation of therapy when toxic 
drug-herb interactions occur. When herbs are combined with drugs with narrow 
therapeutic indices, the monitoring of plasma drug concentrations and observing of 
potential toxicities should be conducted. Predicting the risks for potential drug–herb 
interactions following proper pharmacokinetic principles that are used for predicting 
drug-drug interactions and in vitro–in vivo extrapolation is likely. A fourth approach 
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for circumventing toxicity arising from drug-herb interactions is proper design of 
drugs with minimal potential for herbal interaction. 
 
8 Conclusions and future perspectives 
A major safety concern is the potential for interactions of herbal products with 
prescribed drugs. This issue is especially important with respect to drugs with narrow 
therapeutic indexes (e.g. warfarin and digoxin) [65]. This may lead to adverse 
reactions that are sometimes life-threatening or lethal [40]. The identification of drugs 
that interact with herbs has important implications in drug development. It appears 
that any new drugs that are substrates for CYP3A4 and/or P-gp have a potential to 
cause herb-drug interactions. Thus, caution should be taken when these drugs are 
coadministered with herbs. Since in vitro drug-drug and drug-CYP interaction studies 
have been incorporated into drug development, drug-herb and herb-CYP interactions 
should also be included to identify drugs that interact with herbs in the early stage of 
drug development. 
 
Clinicians should adopt proper strategies to minimize toxic drug-herb interactions. 
Early identification of drugs that interact with herbs and the mechanism involved is 
important. Identification of drugs that interact with herbs can be incorporated into the 
early stages of drug development.  
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Table 1. Drugs that interact with herbal medicines in humans. 
 
Drugs Interacting  
herb 
Study type & subject 
No.  
Interaction outcome Possible mode of 
interaction 
References 
Acetaminophen Garlic BAC; 16 HV Increased sulfation Induction of 
enzyme 
[66] 
Alprazolam SJW BAC; 7 HV ↓AUC by 41%, t1/2 by 24%; ↑ 
Cmax by 15% (P > 0.05) 
Minor induction 
of CYP3A4 
[67] 
Amitriptyline SJW Open BAC; 12 PTS ↓AUC (amitriptyline) by 22% 
and nortriptyline by 41% 
Induction of 
CYP3A 
[68] 
Aspirin Ginkgo Case report Spontaneous hyphema Additive effect [69] 
Chlorpropamide Garlic Case report Hypoglycemic response Additive effect [47] 
Cyclosporine SJW Case report & series; 
88 PT 
↓blood concentration and 
rejection events 
Induction of 
enzyme and PgP 
[70-78] 
 SJW BAC; 11 PTS ↓AUC by 46%, Cmax by 42%, 
Ctrough by 41%, altered 
metabolite profiles 
Induction of 
enzyme and PgP 
[79] 
Digoxin SJW Placebo-controlled 
parallel study; 25 
HV 
↓AUC by 25%, Cmax by 33%, 
Ctrough by 26%, 
PgP induction [80] 
 Siberian 
ginseng 
Case report; 1 PT ↑digoxin concentration Interference with 
assay? 
[81] 
Fexofenadine SJW Open BAC; 12 HV ↓Cmax by 45% and oral CL by 
20% (single dose of herb) 
PgP inhibition [82] 
Fluindione Garlic Case report ↓INR Additive effect [83] 
Imatinib SJW Open crossover; 10 
HV 
↓AUC by 32%, Cmax by 29% CYP3A induction [84] 
 SJW Open fixed-
sequence; 12 HV 
↓AUC by 30%, ↑CL by 42% CYP3A induction [85] 
Indinavir SJW BAC; 8 HV ↓AUC by 57%,  Ctrough by 81% Enzyme induction [86] 
 Milk Thistle Open crossover, 10 
HV 
↓AUC by 9%, ↓ trough level 
(C8) by 25% 
Modulation of 
CYP3A and PgP 
[87] 
Irinotecan SJW Open BAC; 5 PTS ↓SN-38 by 42%, Modulation of [88] 
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↓myelosuppression  PgP? 
Loperamide SJW Case report; 1PT Acute delirium episode MAO inhibition [89] 
Levodopa Kava Case report ↑ “off” period Unknown [90] 
Methadone SJW Case series; 4 PTS ↓Ctrough by 47%  Enzyme induction [91] 
Midazolam  SJW BAC; 12 HV ↑oral CL by 108.9% and ↓oral 
bioavailability by 39.3%; 
↓20% of AUC (i.v.) 
Induction of 
CYP3A4 
[92] 
 SJW BAC; 21 HV ↑1.5-fold (i.v.) and 2.7-fold 
(oral) of CL. 
Induction of 
CYP3A4 
[30] 
Nefazodone SJW Case report; 1PT Nausea, vomiting, headache Additive effect on 
serotonin uptake 
inhibition, enzyme 
inhibition? 
[34] 
Nevirapine SJW Case report; 1 PT ↑CL Induction of 
Enzyme and PgP 
[93] 
Nifedipine SJW BAC, 12 HV Nifedipine: Cmax↓38.5%, 
AUC↓44.9% 
Dehydronifedipine: 
Cmax↑55.9%, AUC↑25.7% 
Induction of 
CYP3A4 
[94] 
Omeprazole SJW 12 HV, crossover Induced metabolism Induction of 
CYP2C9 
[95] 
Paroxetine SJW Case report; 1 PT Nausea, weakness, lethargy Additive effect on 
serotonin uptake 
inhibition, enzyme 
inhibition? 
[35] 
Oral 
contraceptives 
SJW Single-blind 
sequential, 16 HV 
↓13-15% in norethindrone and 
ethinyl estradiol levels. 
↑breakthrough bleeding  
Enzyme induction [96] 
Phenelzine SJW, ginseng Case report Serotonin syndrome Additive effect [44,66] 
Phenprocoumon SJW Single-blind, 
placebo-controlled, 
crossover; 10 HV 
↓AUC by 17.4% Enzyme 
induction? 
[97] 
Procyclidine Betel nut Case reports Severe extrapyramidal 
symptoms (rigidity, tremor, 
Antagonism of 
procyclidine by 
[98] 
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bradykinesis) arecoline 
Propranolol Piperine Open crossover; 6 
HV 
time to Cmax,  ↑Cmax and AUC CYP1A2 
inhibition 
[99] 
Saquinavir Garlic Open crossover, 10 
HV 
↓AUC by 51%, ↓C8h by 49%, 
↓Cmax by 54% 
Induction of 
CYP3A4 and PgP 
[100] 
Sertraline SJW Case series; 5 PTS Nausea, vomiting, anxiety, 
confusion, restlessness, manic 
episode 
Additive effect on 
serotonin uptake 
inhibition, enzyme 
inhibition? 
[34,36] 
Simvastatin SJW Double-blind, 
crossover; 16 HV 
↓Cmax & AUC of simvastatin 
hydroxy acid 
Induction of 
enzyme and PgP 
[101] 
Tacrolimus SJW BAC; 10 PTS ↓AUC by 57.8% Induction of 
enzyme and PgP 
[102] 
Theophylline Piperine Open crossover; 6 
HV 
↑Cmax, t1/2, AUC Inihhition of 
enzymes 
[99] 
 SJW Case report; 1 PT ↓blood level Enzyme induction [103] 
Tolbutamide SJW BAC; 12 HV ⇔AUC, CL, Cmax, Vd, t1/2β, 
↑hypoglycemia episode 
Additive effect? [92] 
Trazodone Ginkgo Case report Coma Unknown [46] 
Voriconazole SJW Controlled, open-
label, 16 HV 
↓AUC by 59%; ↑oral CL by 
144% 
Enzyme induction [104] 
Warfarin SJW, 
Matricaria 
chamomilla 
Case series; 7PTS ↓INR Enzyme induction [77,105] 
 Garlic Case report; 1 PT ↑INR and clotting time Additive effect [106] 
 Donggui Case reports; 2 PTS ↑INR and bruise Herb as COX 
inhibitor 
[107,108] 
 Ginkgo Case report; 1 PT PT16.9, PTT35.5, left parietal 
hemorrhage 
Additive effect [109] 
 Ginseng Case report; 1 PT ↓INR to 1.5 Additive effect [110] 
 Danshen Case reports; 3 PTS ↑INR Additive effect [45,107,111] 
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AUC = area under the plasma concentration-time curve; BAC = before and after comparison; Cmax = maximum plasma concentration; CL = 
clearance; HV = Healthy volunteers; INR = internationally normalized ratio; MAO = Monoamine oxidase; PTS = Patients; SJW = St John’s 
wort; t1/2β = elimination half-life. ↑ = Increase; ↓ = Decrease; ⇔ = Unchanged. 
25 
 
Figure legends 
 
Figure 1. Possible mechanisms for drug interactions with combined herbal medicines. 
As for drug-drug interactions, both pharmacokinetic and pharmacodynamic 
components may play important roles in herbal interactions with prescribed drugs. 
Alterations in absorption, metabolism, distribution or excretion of drugs are the cause 
for pharmacokinetic interactions. Inhibition and induction of drug metabolizing 
enzymes (e.g. cytochrome P450 3A4) and drug transporters (e.g. P-glycoprotein) are 
the major mechanism underlying many pharmacokinetic drug-herb interactions. 
Furthermore, a herb may potentially mimic, increase, or reduce the effects of co-
administered drugs through simultaneous effects on the same drug targets (e.g. 
enzymes or receptors). 
 
 
Figure 2. Possible clinical outcomes when a drug interacts with combined herbal 
medicines. When the clearance of a drug is significantly altered, or its drug targets are 
identical as the herbal components, a clinically important drug interaction with herbs 
may occur. Combined use of herbal medicines may alter drug efficacy, leading to 
over- or under-treatment. Moreover, a drug-herb interaction may cause adverse 
reactions that may be minor, moderate, life-threatening or lethal. 
 
Figure 3. Various approaches to identifying drugs that may interact with herbal 
medicines. These approaches include in silico, in vitro and in vivo (animal and 
human) models. The hierarchy shows the increased cost but decreased ability of 
conducting high throughput studies from in silico to human studies. These models are 
26 
 
often used in combination to obtain enough information that is useful for providing 
warning and proper advice to patients in clinical practice. 
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